Stock Analysis
Guardant Health, Inc. Common StockGH
Sector: Healthcare · Industry: Services-Medical Laboratories
AnalystsStrong Buy35 analystsPrice is 76% of the way from the year's low to its high.
PMP Verdict
Weak fundamentals, expensive
Risks
- Valuation25
- Profitability0
Weak fundamentals at a demanding price.
Market context
-4.4% today· Z 2.0σ
Bull Case
- ✓Altman Z 4.0 — safe-zone balance sheet
- ✓Revenue CAGR 27.3% — durable top-line growth
What's happening with GH
Profile
profitability, moat, valuation, growth and earnings quality lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-1.1%)0/25
- P/S (17.8x)5/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (27.3%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (n/a)0/25
- Net margin (-38.3%)0/25
- Operating margin (-39.7%)0/25
- Financial Health50/100 · Moderate
- Altman Z (3.96)25/25
- Current ratio (4.84)25/25
- Interest coverage (-154.5x)0/25
- Net cash / debt (n/a)0/25
- Quality40/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (-3.21)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 32.2%)0/25
- Moat0/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (-94.5%)0/25
- FCF-positive years (0/8 yrs)0/25
- Worst-year net margin (worst -145.6%)0/25
Risk Flags
- ⚠Negative FCF margin (-0.2%) — burning cash
- ⚠SBC 16.2% of revenue — real dilution cost
- ⚠8 loss-making years in recent history
- ⚠Interest coverage -154.5× — thin debt cushion
About Guardant Health, Inc. Common Stock
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. Show more
The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Headquarters: PALO ALTO, CA · Employees: 2,506 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-1.1%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -19.4%–-1.0% · 96th pct
P/S (TTM)17.78xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.2x–40.1x · 86th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales19.2xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-10.30A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA-25.5%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-38.3%D
Grade D: LowNet Income / Revenue
Operating Margin-39.7%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin65.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-20.3%D
Grade D: LowFCF / Revenue
True FCF Margin-36.5%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR27.3%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+32.8%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue16.2%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
50CAltman Z-Score3.96A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.84xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.53xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-154.5xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
40D+Piotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-3.21A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability32.2%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue4.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.66xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Azar Alex M II Filed | Azar Alex M II | SellOpen market sale | -69 | |
Azar Alex M II Filed | Azar Alex M II | Option exercise | -137 | |
Azar Alex M II Filed | Azar Alex M II | Option exercise | +137 | |
Chudova Darya Filed | Chudova Darya | Option exercise | -1701 | |
Chudova Darya Filed | Chudova Darya | Option exercise | -3324 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Chudova Darya Filed | Chudova Darya | Option exercise | -1668 | |
Chudova Darya Filed | Chudova Darya | Option exercise | -1340 | |
Chudova Darya Filed | Chudova Darya | Tax withholding | -4320 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)-94.5%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/8 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-145.6%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$7.88
Cash & short-term investments per share (Finnhub)
Book Value / Share$0.57
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$1.20B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-99.31M
Shareholders' equity (book value)
Asset / Liability0.95xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$21.03B
Current Market Capitalization
Beta1.70C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Guardant Health, Inc. Common Stock (GH)
GH is down 4.39% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Guardant Health, Inc. Common Stock. Altman Z-Score of 3.96 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -3.21 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 27% annually — a strong growth profile.
- Free-cash-flow margin is negative (-20%) — the business currently burns cash.
- Interest coverage of -154.5× leaves little room for earnings shocks.
- Guardant Health, Inc. Common Stock posted a net loss in 8 of 8 available completed fiscal years (2018–2025).
- At a valuation score of 25/100, GH trades at a premium to its historical multiples.
See how GH ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all GH moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 6 | Regular | 172.10 | -8.08% | -3.47 |
| Oct 6 | After-hours | 169.00 | -9.73% | -4.15 |
| Oct 5 | After-hours | 188.04 | +5.76% | 2.06 |
| Sep 21 | Regular | 173.39 | -3.34% | -2.23 |
| Sep 21 | After-hours | 173.87 | -3.07% | -2.05 |
Frequently Asked Questions about GH
What is the current Guardant Health, Inc. Common Stock (GH) stock price?
GH is trading at $158.60 at the last market close, down 4.39% on the session. PreMarketPrice tracks GH pre-market, intraday and after-hours prices.
Is GH stock a buy right now?
PreMarketPrice's quantitative model rates Guardant Health, Inc. Common Stock's financial health at 50/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is GH stock overvalued?
Guardant Health, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Guardant Health, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for GH. The Earnings section lists recent reports and updates as dates are announced.
What sector does Guardant Health, Inc. Common Stock operate in?
Guardant Health, Inc. Common Stock operates in the Healthcare sector, within the Services-Medical Laboratories industry. The Related Stocks section lists sector peers for comparison.
What does Guardant Health, Inc. Common Stock do?
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use.
About Guardant Health, Inc. Common Stock (GH) Stock
Guardant Health, Inc. Common Stock (GH) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry. As of the latest update, Guardant Health, Inc. Common Stock is trading at $158.60, down 4.39% on the day with a market capitalization of $21.0 billion. The financial health score for GH is 50/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for GH stock.
GH Stock Analysis & Key Metrics
On PreMarketPrice, you can track Guardant Health, Inc. Common Stock (GH) across multiple dimensions:
- Pre-market price & movement: Real-time GH stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for GH with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Guardant Health, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 50/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for GH.
- Sector peers: Compare GH against 6 other healthcare stocks on key financial metrics.
Is GH a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Guardant Health, Inc. Common Stock (GH) as an investment. The financial health score of 50/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Guardant Health, Inc. Common Stock (GH) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.